Drugs / nicoboxil
nicoboxil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02300311 | Jan → May 2015 | — | Boehringer Ingelheim | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01708915 Comparator | Oct 2012 → Apr 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nicoboxil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01708915 ↗ |
| Known as | Beta-butoxyethyl nicotinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105161 ↗ |
| Known as | Butoxyethyl nicotinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105161 ↗ |
| Known as | Nicoboxilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105161 ↗ |
| Modality | Small molecule | — CHEMBL2105161 ↗ |
| Route | Topical | “topical nicoboxil 2.5%/nonivamide 0.4%” PMID 25929250 ↗ Apr 2015 |